846 related articles for article (PubMed ID: 11799102)
21. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
Buczko W; Hermanowicz JM
Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
[TBL] [Abstract][Full Text] [Related]
23. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
[TBL] [Abstract][Full Text] [Related]
24. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
[TBL] [Abstract][Full Text] [Related]
25. Enalapril in treatment of hypertension with renal artery stenosis. Changes in blood pressure, renin, angiotensin I and II, renal function, and body composition.
Hodsman GP; Brown JJ; Cumming AM; Davies DL; East BW; Lever AF; Morton JJ; Murray GD; Robertson JI
Am J Med; 1984 Aug; 77(2A):52-60. PubMed ID: 6089557
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
[TBL] [Abstract][Full Text] [Related]
27. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
Jensen J; Henik RA; Brownfield M; Armstrong J
Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
[TBL] [Abstract][Full Text] [Related]
28. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
30. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
Goldberg MR; Bradstreet TE; McWilliams EJ; Tanaka WK; Lipert S; Bjornsson TD; Waldman SA; Osborne B; Pivadori L; Lewis G
Hypertension; 1995 Jan; 25(1):37-46. PubMed ID: 7843751
[TBL] [Abstract][Full Text] [Related]
31. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
[TBL] [Abstract][Full Text] [Related]
32. [INTERACTION OF BETA-BLOCKER PROPRANOLOL WITH RENIN-ANGIOTENSIN SYSTEM INHIBITORS IN RAT KIDNEY].
Kuzmin OB; Buchneva NV; Landar LN
Eksp Klin Farmakol; 2016; 79(3):27-30. PubMed ID: 27455575
[TBL] [Abstract][Full Text] [Related]
33. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
Stanton A; Jensen C; Nussberger J; O'Brien E
Hypertension; 2003 Dec; 42(6):1137-43. PubMed ID: 14597641
[TBL] [Abstract][Full Text] [Related]
34. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.
Stephan D; Grima M; Welsch M; Barthelmebs M; Vasmant D; Imbs J
Fundam Clin Pharmacol; 1996; 10(5):474-83. PubMed ID: 8902551
[TBL] [Abstract][Full Text] [Related]
35. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
[TBL] [Abstract][Full Text] [Related]
36. Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man.
Yee KM; Struthers AD
Br J Clin Pharmacol; 1998 Dec; 46(6):583-8. PubMed ID: 9862248
[TBL] [Abstract][Full Text] [Related]
37. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
[TBL] [Abstract][Full Text] [Related]
38. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
39. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition.
De'Oliveira JM; Price DA; Fisher ND; Allan DR; McKnight JA; Williams GH; Hollenberg NK
Kidney Int; 1997 Sep; 52(3):771-7. PubMed ID: 9291199
[TBL] [Abstract][Full Text] [Related]
40. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 May; 66(5):497-502. PubMed ID: 20179914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
